2/22
09:32 am
grcl
Gracell Biotechnologies Inc. (NASDAQ: GRCL) had its "hold" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $10.25 price target on the stock, down previously from $11.00.
Neutral
Report
Gracell Biotechnologies Inc. (NASDAQ: GRCL) had its "hold" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $10.25 price target on the stock, down previously from $11.00.
2/22
08:45 am
grcl
Gracell Biotechnologies Acquisition Completed
Neutral
Report
Gracell Biotechnologies Acquisition Completed
2/20
07:45 am
grcl
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement
Low
Report
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement
2/8
02:50 am
grcl
Astra Sees Stronger Profit, Sales Growth on Cancer Drugs [BNN Bloomberg (Canada)]
Neutral
Report
Astra Sees Stronger Profit, Sales Growth on Cancer Drugs [BNN Bloomberg (Canada)]
1/29
07:02 am
grcl
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma [Yahoo! Finance]
Low
Report
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma [Yahoo! Finance]
1/29
07:00 am
grcl
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Low
Report
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma